![](/images/graphics-bg.png)
CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience
المؤلفون المشاركون
Sahu, Arvind
Jefford, Michael
Lai-Kwon, Julia
Thai, Alesha
Hicks, Rodney J.
Michael, Michael
المصدر
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-02-20
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Introduction.
Capecitabine-temozolomide (CAPTEM) has significant activity in patients (pts) with metastatic low grade pancreatic neuroendocrine tumors (NETs).
However, there is limited data regarding its activity in pts with metastatic well-differentiated intermediate and high grade pancreatic and nonpancreatic NETs.
The objective of this study was to assess the functional imaging response, survival, and tolerability of CAPTEM in this population.
Methods.
A retrospective audit of pts with metastatic well-differentiated intermediate (WHO grade 2) or high grade (WHO grade 3) NETs treated at Peter MacCallum Cancer Centre between March 2013 and March 2017.
Pts received capecitabine 750 mg/m2 orally twice daily (bd) from days1 to 14 and temozolomide 100 mg/m2 bd from days 10 to 14 every 28 days.
Data regarding functional imaging response, progression-free and overall survival, and toxicities was collected.
Results.
Thirty-two pts received a median of 6 cycles (range: 2-16) of CAPTEM for grade 2 (n=21, 66%) or grade 3 (n=11, 34%), Ki67 <55% (n= 7, 21.9%) or Ki67 ≥55% (n= 4, 12.5 %) NET.
Primary site included gastroenteropancreatic (n= 17, 53%), lung (n= 12, 37.5%), and unknown origin (n = 3, 9.4%).
Twenty-two percent received CAPTEM as first-line therapy.
After a median of 31 months of follow-up, the two-year overall survival (OS) was 42%, with a median OS of 24 months.
There was a trend towards improved median progression-free survival (PFS) in pts with low grade 3 (Ki67<55%) versus high grade 3 (Ki67 ≥55%) NETs (15 vs 4 months, p= 0.11).
Ten (31.3%) experienced grade 3/4 toxicity, with nausea (15.6%), thrombocytopaenia (12.5%), and fatigue (9.4%) the most common toxicities reported.
Conclusion.
CAPTEM has significant activity in patients with metastatic grades 2 and 3 NETs with manageable toxicity.
The PFS benefit observed in the grade 3 subgroup with Ki67<55% warrants further evaluation in a larger randomized trial.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Sahu, Arvind& Jefford, Michael& Lai-Kwon, Julia& Thai, Alesha& Hicks, Rodney J.& Michael, Michael. 2019. CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience. Journal of Oncology،Vol. 2019, no. 2019, pp.1-7.
https://search.emarefa.net/detail/BIM-1184657
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Sahu, Arvind…[et al.]. CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience. Journal of Oncology No. 2019 (2019), pp.1-7.
https://search.emarefa.net/detail/BIM-1184657
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Sahu, Arvind& Jefford, Michael& Lai-Kwon, Julia& Thai, Alesha& Hicks, Rodney J.& Michael, Michael. CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience. Journal of Oncology. 2019. Vol. 2019, no. 2019, pp.1-7.
https://search.emarefa.net/detail/BIM-1184657
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1184657
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)